Tirzepatide's approval for weight loss: what changed, and what it means for you

Step 1: the regulatory process that brought tirzepatide to UK patients

Before any medicine reaches a patient in the UK, it must pass through a formal licensing process run by the MHRA. For tirzepatide, that process involved reviewing data from the SURMOUNT clinical programme — a series of large-scale trials involving thousands of adults with obesity or overweight across multiple countries. The MHRA assessed safety, quality and efficacy before granting a marketing authorisation under the brand name Mounjaro.

Because tirzepatide is a new medicine, it carries a Black Triangle (▼) designation, meaning the MHRA collects additional data on its use in everyday clinical practice. This is standard for recently approved medicines and does not indicate an unusual safety concern. You can read the background to the UK approval process on the tirzepatide approval page, which covers the regulatory timeline in more detail.

Once licensed, the medicine became available via private prescription immediately. NHS availability followed a separate route through NICE.

Step 2: what NICE's recommendation added on top of the licence

A licence tells prescribers a medicine is safe and effective for a defined population. A NICE technology appraisal tells the NHS whether it represents value for money and, if so, for whom. Tirzepatide's NICE appraisal, published in December 2024 as TA1026, recommended it for NHS use, but with eligibility criteria narrower than the licence.

The NICE thresholds require a BMI of 35 or above alongside at least one qualifying comorbidity. Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, where the adjustment is 2.5 kg/m² throughout. NHS access is also being rolled out in phases: from June 2025 for those with a BMI of 40-plus and four or more qualifying conditions; from around June 2026 for the 35–39.9 BMI group with four or more conditions. Every NHS patient must also take part in structured diet and activity support alongside the medicine.

Private treatment through a regulated pharmacy operates under the licensed criteria rather than the NICE thresholds, so people who do not yet qualify for NHS treatment may still be clinically suitable. The Mounjaro weight-loss approval page lays out both sets of criteria side by side.

Step 3: what the trial evidence showed about weight loss

The headline results came from SURMOUNT-1, a 72-week randomised trial. At the 15 mg maintenance dose, participants lost around 20–21% of their body weight on average, with some analyses placing the figure slightly higher. Those are the figures NICE reviewed when making its recommendation. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4 mg and found tirzepatide produced greater average weight loss over 72 weeks in adults with obesity and no diabetes.

It is worth being clear about what these numbers represent: they are averages from controlled trial populations, not predictions for any individual. Results vary based on starting weight, adherence, lifestyle changes and how the body responds to treatment. The tirzepatide and weight loss page goes deeper into what the evidence shows and what shapes individual outcomes.

One practical point that trips people up early: the 2.5 mg pen is not the therapeutic dose. It exists to give the body time to adjust before stepping up, which matters for managing nausea and other gastrointestinal effects in the first weeks. Many patients keep that starter pen in the fridge door alongside everyday items as a reminder that it is part of a longer process, not the destination.

What approval means in practice for accessing treatment

Tirzepatide's licensed status means a GPhC-registered prescriber can legally issue a private prescription after a clinical assessment. It does not mean any adult can simply purchase it. The assessment exists because the medicine is not appropriate for everyone: it is not licensed for use in pregnancy, breastfeeding or for those trying to conceive, and it is not indicated for people under 18, as the Mounjaro age approval criteria explain in detail. A history of certain conditions (including pancreatitis or medullary thyroid carcinoma) requires careful prescriber review.

For women using oral contraceptives, the MHRA advises adding a non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, as the medicine may affect how the pill is absorbed. The NHS tirzepatide medicines page covers safety information including interactions in plain language.

If you are considering private treatment, you can explore the full range of licensed options on the weight-loss treatments page. A private route does not require a GP referral or a waiting list, but it does require exactly the same clinical rigour: identity verification, weight confirmation, a review of your health history and a prescriber's decision. For a broader overview of how tirzepatide fits into the weight-loss medicine landscape, the tirzepatide overview is a useful starting point.

Cost is a question that comes up naturally alongside the approval story. The Mounjaro price comparison page explains what private treatment typically costs across providers and what legitimate pricing should include (clinical assessment, prescription, delivery and aftercare) so you can read it before making any decisions.